• The specific situation of the patient. Unless otherwise provided for by national regulations,
off-label use of medication should be limited to situations where it is in the patient's interest …

The recommendations listed in this guideline are, whenever possible, evidence based. An
initial extensive evidence review, which included literature derived from research involving …

Aim This executive summary of the hypertrophic cardiomyopathy clinical practice guideline
provides recommendations and algorithms for clinicians to diagnose and manage …

In view of the increasing complexity of both cardiovascular implantable electronic devices
(CIEDs) and patients in the current era, practice guidelines, by necessity, have become …

Background: Hypertrophic cardiomyopathy is the leading cause of sudden cardiac death
(SCD) in children and young adults. Our objective was to develop and validate a SCD risk …

Importance Sudden cardiac death (SCD) is the most common mode of death in childhood
hypertrophic cardiomyopathy (HCM), but there is no validated algorithm to identify those at …

Hypertrophic cardiomyopathy (HCM) is a relatively common inherited myocardial disorder,
once regarded as largely untreatable with ominous prognosis and most visibly as a common …

In view of the increasing complexity of both cardiovascular implantable electronic devices
(CIEDs) and patients in the current era, practice guidelines, by necessity, have become …

Many previously unexplained life-threatening ventricular arrhythmias and sudden cardiac
deaths (SCDs) in young individuals are now recognized to be genetic in nature and are …

Aims Current guidelines recommend initiating family screening for hypertrophic
cardiomyopathy (HCM) after age 10 or 12 years unless early screening criteria are met. The …